(Total Views: 595)
Posted On: 08/25/2023 10:32:33 PM
Post# of 151700
I ran across a Twitter (correction: make that X) string about the following trial:
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
https://classic.clinicaltrials.gov/ct2/show/NCT05592418
One of the exclusion criteria was:
18. History of Chronic Fatigue Syndrome prior to COVID-19 infection.
There is a video interview of someone in the trial who apparently did not meet that criteria.
Other posters noted their concerns about how the trial was being run.
The CRO was Amarex Clinical Research.
https://twitter.com/postviraltrials/status/16...0041683356
Perhaps "sloppy" is their current mode of operation.
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
https://classic.clinicaltrials.gov/ct2/show/NCT05592418
One of the exclusion criteria was:
18. History of Chronic Fatigue Syndrome prior to COVID-19 infection.
There is a video interview of someone in the trial who apparently did not meet that criteria.
Other posters noted their concerns about how the trial was being run.
The CRO was Amarex Clinical Research.
https://twitter.com/postviraltrials/status/16...0041683356
Perhaps "sloppy" is their current mode of operation.
(4)
(0)Scroll down for more posts ▼
